These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 32788215)

  • 1. The African natural product knipholone anthrone and its analogue anthralin (dithranol) enhance HIV-1 latency reversal.
    Richard K; Schonhofer C; Giron LB; Rivera-Ortiz J; Read S; Kannan T; Kinloch NN; Shahid A; Feilcke R; Wappler S; Imming P; Harris M; Brumme ZL; Brockman MA; Mounzer K; Kossenkov AV; Abdel-Mohsen M; Andrae-Marobela K; Montaner LJ; Tietjen I
    J Biol Chem; 2020 Oct; 295(41):14084-14099. PubMed ID: 32788215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen.
    Liu H; Hu PW; Dubrulle J; Stossi F; Nikolai BC; Mancini MA; Rice AP
    PLoS One; 2021; 16(4):e0244771. PubMed ID: 33914760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency.
    Schonhofer C; Yi J; Sciorillo A; Andrae-Marobela K; Cochrane A; Harris M; Brumme ZL; Brockman MA; Mounzer K; Hart C; Gyampoh K; Yuan Z; Montaner LJ; Tietjen I
    Biochem Pharmacol; 2021 Apr; 186():114462. PubMed ID: 33577894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.
    Boucau J; Das J; Joshi N; Le Gall S
    PLoS Pathog; 2020 Mar; 16(3):e1008442. PubMed ID: 32196533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Novel HIV-1 Latency-Reversing Agents from a Library of Marine Natural Products.
    Richard K; Williams DE; de Silva ED; Brockman MA; Brumme ZL; Andersen RJ; Tietjen I
    Viruses; 2018 Jun; 10(7):. PubMed ID: 29954099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
    Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
    J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir.
    Dai W; Wu F; McMyn N; Song B; Walker-Sperling VE; Varriale J; Zhang H; Barouch DH; Siliciano JD; Li W; Siliciano RF
    Sci Transl Med; 2022 Oct; 14(667):eabh3351. PubMed ID: 36260688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol Reactivates Latent HIV through Increasing Histone Acetylation and Activating Heat Shock Factor 1.
    Zeng X; Pan X; Xu X; Lin J; Que F; Tian Y; Li L; Liu S
    J Agric Food Chem; 2017 Jun; 65(22):4384-4394. PubMed ID: 28471170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic Chromatin-Modifying Treatments Reactivate Latent HIV and Decrease Migration of Multiple Host-Cell Types.
    Blanco A; Mahajan T; Coronado RA; Ma K; Demma DR; Dar RD
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34201394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
    Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
    mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel selective histone deacetylase I inhibitor CC-4a activates latent HIV-1 through NF-κB pathway.
    Lu W; Yang C; Xu X; Chen C; Hou X; Fang H; Liu S
    Life Sci; 2021 Feb; 267():118427. PubMed ID: 32941894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.